Bessemer Group Inc. Has $1.07 Million Stock Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Bessemer Group Inc. decreased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 68.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,582 shares of the specialty pharmaceutical company's stock after selling 18,350 shares during the quarter. Bessemer Group Inc.'s holdings in Jazz Pharmaceuticals were worth $1,065,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. IFP Advisors Inc purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth $25,000. Bank of New York Mellon Corp increased its stake in Jazz Pharmaceuticals by 5.4% in the fourth quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock valued at $58,835,000 after purchasing an additional 24,481 shares during the last quarter. Oppenheimer Asset Management Inc. increased its stake in Jazz Pharmaceuticals by 24.2% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 9,588 shares of the specialty pharmaceutical company's stock valued at $1,181,000 after purchasing an additional 1,867 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $4,762,000. Finally, Jones Financial Companies Lllp boosted its holdings in shares of Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 130 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Down 0.4%

Jazz Pharmaceuticals stock traded down $0.48 during mid-day trading on Friday, hitting $109.45. The company's stock had a trading volume of 327,049 shares, compared to its average volume of 828,910. The firm's 50 day moving average is $108.96 and its 200 day moving average is $119.08. The company has a market cap of $6.62 billion, a PE ratio of 14.59, a price-to-earnings-growth ratio of 4.72 and a beta of 0.32. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The firm had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. During the same period last year, the business earned $2.68 earnings per share. The firm's revenue for the quarter was down .5% on a year-over-year basis. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Seamus Mulligan acquired 1,621 shares of the business's stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average cost of $103.00 per share, with a total value of $166,963.00. Following the purchase, the director owned 101,621 shares of the company's stock, valued at approximately $10,466,963. The trade was a 1.62% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the transaction, the chief executive officer directly owned 436,973 shares in the company, valued at $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,500 shares of company stock valued at $277,930 over the last ninety days. Company insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on JAZZ. Morgan Stanley decreased their price target on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Wall Street Zen lowered Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Royal Bank Of Canada reduced their price objective on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright upped their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Finally, UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price target for the company from $145.00 to $179.00 in a report on Friday, March 7th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $184.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.